Demographic data, type of cancer, ICI molecules and tumour response according to irAE occurrence
| Rheumatic irAEs (n=35) n (%) | Non-rheumatic irAEs (n=137) n (%) | No irAEs (n=368) n (%) | |
| Age, mean (SD) | 63.8 (11.9) | 65.5 (12.8) | 64.0 (12.9) |
| Gender | |||
| Male | 23 (65.7) | 95 (69.3) | 253 (68.7) |
| Female | 12 (34.3) | 42 (30.6) | 115 (31.2) |
| Tumour type | |||
| Melanoma | 16 (45.7) | 83 (62.0) | 150 (40.7) |
| Merkel | 1 (2.8) | 0 (0) | 4 (1.0) |
| Lung | 12 (34.2) | 17 (12.4) | 103 (27.9) |
| Renal | 6 (17.1) | 13 (9.4) | 55 (14.9) |
| Urothelial | 0 (0) | 2 (1.4) | 12 (3.2) |
| Head and neck | 0 (0) | 11 (8.0) | 18 (4.8) |
| Blood cancer | 0 (0) | 3 (2.1) | 12 (3.2) |
| Gastrointestinal/liver | 0 (0) | 7 (5.1) | 11 (2.9) |
| Lung+head and neck | 0 (0) | 1 (0.7) | 2 (0.5) |
| Glioblastoma | 0 (0) | 0 (0) | 1 (0.2) |
| Cancer therapy | |||
| Anti-CTLA-4 | 0 (0) | 3 (2.1) | 2 (0.5) |
| Anti-PD-1/PD-L1 | 30 (85.7) | 82 (59.8) | 305 (82.8) |
| Sequential or combined | 5 (14.2) | 52 (37.9) | 61 (16.5) |
| Best tumour response | |||
| Responders | 30 (85.7) | 103 (75.1) | 130 (35.3) |
| Complete response | 3 (8.5) | 14 (10.2) | 15 (4.0) |
| Partial response | 11 (31.4) | 33 (24.0) | 45 (12.2) |
| Stable disease | 16 (45.7) | 56 (40.8) | 70 (19.0) |
| Non-responders | 5 (14.2) | 28 (20.4) | 192 (52.1) |
| Unknown | 0 (0) | 6 (4.3) | 46 (12.5) |
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse effects; PD-1, programmed cell death protein 1; PD-L1, PD-1 ligand 1.